Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
14.99 AUD | +0.67% | -1.06% | -6.31% |
Mar. 14 | Clinuvel Pharmaceuticals Launches Share Buyback Program | MT |
Mar. 14 | Morgans Financial Upgrades Clinuvel Pharmaceuticals to Add From Hold; Price Target is AU$16 | MT |
Business Summary
Sales per Business
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Biopharmaceutical
100.0
%
| 66 | 100.0 % | 78 | 100.0 % | +19.17% |
Sales per region
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Europe & United States
92.3
%
| 60 | 91.5 % | 72 | 92.3 % | +20.19% |
Switzerland, Others
7.7
%
| 6 | 8.5 % | 6 | 7.7 % | +8.19% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 61 | 05-10-31 |
Darren M. Keamy
DFI | Director of Finance/CFO | - | 05-10-31 |
Lachlan Hay
COO | Chief Operating Officer | - | 06-12-31 |
Dennis J. Wright
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 61 | 05-10-31 |
Director/Board Member | - | 07-02-05 | |
Karen Agersborg
BRD | Director/Board Member | - | 18-01-28 |
Susan Smith
BRD | Director/Board Member | - | 19-09-22 |
Chairman | - | 19-11-25 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 50,127,270 | 39,883,495 ( 79.56 %) | 0 | 79.56 % |
Company contact information
Clinuvel Pharmaceuticals Ltd.
535 Bourke Street Level 11
3000, Melbourne
+61 3 9660 4900
http://www.clinuvel.comSector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.31% | 484M | |
-2.86% | 87.37B | |
+3.95% | 41.01B | |
-21.94% | 28.08B | |
+53.11% | 24.72B | |
-5.41% | 17.47B | |
-44.23% | 11.69B | |
-17.60% | 11.6B | |
-13.96% | 11.56B | |
-0.22% | 8.44B |
- Stock Market
- Equities
- CUV Stock
- Company Clinuvel Pharmaceuticals Limited